Answer to Question 1
Correct Answer: 1
Rationale 1: Despite much research, scientists are far from developing a vaccine to prevent HIV.
Rationale 2: The HIV vaccines that have been researched cannot prevent fatal consequences of the virus.
Rationale 3: There are not many HIV vaccines in clinical trial.
Rationale 4: Despite much research, scientists are far from developing a vaccine to prevent AIDS.
Global Rationale: After decades of research, the FDA has not approved a single vaccine. Only a few HIV vaccines are currently in clinical trials, and none is expected to cause a major impact on the HIV epidemic. At best, the HIV vaccines produced thus far only boost the immune response; they are unable to prevent the infection.
Answer to Question 2
Correct Answer: 1,3,5
Rationale 1: This medication should be taken once a day, which increases compliance.
Rationale 2: This medication must be taken once daily.
Rationale 3: This medication is associated with fewer adverse effects than other antiretroviral medication.
Rationale 4: This medication cannot be taken in clients with HBV infections.
Rationale 5: This medication is pregnancy category B and is safe to take during pregnancy.
Global Rationale: Emtricitabine has the advantage of once-daily dosing and fewer adverse effect. It carries a black box warning that it should not be administered to patients coinfected with HBV because severe exacerbations of HBV symptoms may occur after discontinuation of emtricitabine. Emtricitabine is one of the preferred drugs for initial HIV therapy. This drug is pregnancy category B.